A multi-strain probiotic formulation (10B CFU) stabilized in a VBNC (Viable But Non-Culturable) state and fortified with Galacto-oligosaccharides (GOS).

1. The Core

G1 is engineered to provide "Total-Gut Coverage" by utilizing species with distinct environmental preferences:

• Upper-GI Defense: Lactobacillus acidophilus and L. bulgaricus (2B CFU each) act as the first line of defense. They aggressively lower local pH through lactic acid production, inhibiting pathogens like E. coli and Salmonella [6].
• The Immunological Bridge: Lactobacillus casei (2B CFU) is highly resistant to gastric transit and serves to modulate the Gut-Associated Lymphoid Tissue (GALT), supporting systemic immunity [3].
• Lower-GI Colonization: Bifidobacterium longum and B.bifidum (2B CFU each) reside in the colon, where they ferment complex fibers to maintain the mucosal barrier and produce essential vitamins [5].

2. Advanced Synergy

The 23-year success of G1 is attributed to two specific synergistic pathways:

• Lactobacillus species consume residual oxygen in the small intestine. This "scrubbing" action creates the strictly anaerobic environment necessary for Bifidobacteria to thrive in the colon.
• Lactobacillus produces lactate as a byproduct. In a healthy gut relay, this lactate is utilized byBifidobacteriaand other commensal flora to produce Butyrate— the primary energy source for the cells lining the colon (colonocytes).

3. VBNC & GOS Technology

• VBNC Induction: Strains are induced into a "suspended" state via species-specific cold stress. This ensures thickened cell walls for maximum protection against gastric acid [4, 8].
• Resuscitation via GOS: GOS is included as a selective "starter fuel". Because Bifidobacteria have specialized enzymes to utilize GOS more efficiently than pathogens, they out-compete "bad" bacteria immediately upon "waking up" in the gut [1].

4. FAQ

Q: Why choose 10B CFU over higher-dosed competitors?

A: Effectiveness is based on viability, not input. Standard "active" probiotics suffer massive "die-off" in the stomach. G1's VBNC cells act as a "sleeping army," passing through the stomach protected and resuscitating at the target site with nearly 100% efficiency.

Q: Is the product safe for lactose-intolerant patients?

A: Yes. L. bulgaricus and L. acidophilusare prolific producers of $\beta$-galactosidase, which helps the patient digest lactose, often reducing the symptoms of dairy sensitivity.

Q: How should the cold chain be managed in a clinical setting?

A: Store between 2°C and 8°C. While the VBNC state is resilient, extended exposure to heat can trigger "premature resuscitation," causing the bacteria to exhaust their energy reserves before they reach the patient's gut.

References

1. Akiyama, T., et al. (2015). GOS consumption by Bifidobacteria. Bioscience, Biotechnology, and Biochemistry.

2. Dempsey, E., & Corr, S. C. (2022). Lactobacillus spp. for GI Health. Frontiers in Immunology.

3. Galdeano, C. M., & Perdigόn, G. (2006). L. casei and mucosal immunity. Clinical and Vaccine Immunology.

4. Li, L., et al. (2014). The VBNC state in probiotics. Frontiers in Microbiology.

5. Yao, S., et al. (2021). B. Longum and IBD protection. Journal of Immunology Research.

6. Pakdaman, M. N., et al. (2016). L. acidophilus and lactose intolerance. Journal of Functional Foods.

7. Vulevic, J., et al. (2008). GOS and the fecal microbiota. The Journal of Nutrition.

8. Signoretto, C., et al. (2000). Cell wall changes in VBNC states. Applied and Environmental Microbiology.